Is Ensidipine available in Myanmar?

Ensidipine (enasidenib) is an anti-tumor targeted drug used to treat relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutations. Ensidipine is manufactured by Celgene and Agios was jointly developed by pharmaceutical companies and was approved for marketing in 2017 year8month1 by the Nikkei U.S.FDA. It has not been marketed in China.

There is no officially marketed version of ensidipine in Myanmar. Currently, the officially marketed generic drugs include the Bangladeshi version and the Lao version. Therefore, patients must be cautious when purchasing overseas drugs and ensure that they buy regular drugs so that the quality of the drugs can be 100% guaranteed. The retail price of Ziska Pharmaceuticals in Bangladesh50mg60tablets4 is about one thousand yuan, the retail price of Everest Pharmaceuticals in Bangladesh50mg30tablets5are about 1,000 yuan, and the retail price of Lucius Pharmaceuticals in Laos is 2about 1,000 yuan. They all have government approvals. Patients can choose the drug version according to their own financial situation.

The recommended dose of ensidipine in the package insert is 100 mg orally once daily until disease progression or unacceptable toxicity occurs. Ensidipine side effects includeincreased total bilirubin (81%), decreased calcium (74%), nausea (50%), Diarrhea(43%), Decreased potassium (41%), Vomiting (34%), Loss of appetite (34%), Decreased phosphorus content(27%), Differentiation syndrome(14%), Non-infectious leukocytosis(12%), Disturbance of taste pan> (12%), pulmonary edema (≤10%), acute respiratory distress syndrome (≤10%), tumor lysis syndrome (6%), etc. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.